Loading ETF profile…
This exchange-traded fund (ETF) endeavors to match the capital appreciation and income generation of the LifeSci Biotechnology Clinical Trials Index, disregarding fees and expenses. The underlying index focuses on tracking the financial progress of a carefully chosen group of biotechnology firms engaged in clinical trials. It is important to note that, as of February 27, the fund's official name transitioned from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| QURE | uniQure NV | 1.20% | $552.83K |
| APGE | Apogee Therapeutics Inc | 1.02% | $467.60K |
| RGNX | REGENXBIO Inc | 1.01% | $464.35K |
| DFTX | Definium Therapeutics Inc | 0.99% | $454.35K |
| JBIO | Jade Biosciences Inc | 0.97% | $445.13K |
| MNPR | Monopar Therapeutics Inc | 0.93% | $425.20K |
| FDMT | 4D Molecular Therapeutics Inc | 0.89% | $408.31K |
| BHVN | Biohaven Ltd | 0.89% | $407.25K |
| MBX | MBX Biosciences Inc | 0.88% | $406.05K |
| CGEM | Cullinan Therapeutics Inc | 0.88% | $402.69K |
| REPL | Replimune Group Inc | 0.87% | $399.71K |
| RCKT | Rocket Pharmaceuticals Inc | 0.85% | $392.19K |
| NTLA | Intellia Therapeutics Inc | 0.85% | $391.41K |
| DSGN | Design Therapeutics Inc | 0.85% | $389.30K |
| SANA | Sana Biotechnology Inc | 0.85% | $388.51K |
| GENB | Generate Biomedicines Inc | 0.84% | $387.39K |
| BIOA | BioAge Labs Inc | 0.84% | $384.55K |
| AKTS | Aktis Oncology Inc | 0.83% | $382.81K |
| MGTX | MeiraGTx Holdings plc | 0.83% | $382.76K |
| SLDB | Solid Biosciences Inc | 0.83% | $382.64K |
| EVMN | Evommune Inc | 0.83% | $380.09K |
| RZLT | Rezolute Inc | 0.83% | $379.97K |
| IVVD | Invivyd Inc | 0.82% | $377.25K |
| VKTX | Viking Therapeutics Inc | 0.82% | $376.33K |
| AVTX | Avalo Therapeutics Inc | 0.82% | $375.46K |